Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study
DOI:
https://doi.org/10.2340/1651-226X.2024.39851Keywords:
Gastrointestinal stromal tumour, GIST, imatinib, Oligometastatic disease, Survival, Quality of LifeAbstract
Introduction: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended. We investigated whether selected patients with metastatic GIST may remain in durable remission despite imatinib discontinuation.
Patients: In this 1-group, prospective, multicentre phase II trial selected patients with oligometastatic (≤3 metastases) GIST discontinued imatinib treatment. Eligible patients had been treated with imatinib >5 years without progression and had no radiologically detectable metastases after metastasectomy, radiofrequency ablation (RFA) or complete response to imatinib. The primary endpoint was progression-free survival (PFS) 3-years after stopping imatinib. Overall survival (OS) and quality of life (QoL) were secondary endpoints.
Results: The trial closed prematurely due to slow accrual. Between January 5, 2017, and June 5, 2019, 13 patients were enrolled, of whom 12 discontinued imatinib. The median follow-up time was 55 months (range, 36 to 69) after study entry. Five (42%) of the 12 eligible patients remained progression free, and seven (58%) progressed with a median time to progression 10 months. Median PFS was 23 months and the estimated 3-year PFS 41%. Six of the seven patients who progressed restarted imatinib, and all six responded. Three-year OS was 100%, and all patients were alive at the time of the study analysis. QoL measured 5 and 11 months after discontinuation of imatinib demonstrated improvement compared to the baseline.
Interpretation: A substantial proportion of selected patients with oligometastatic GIST treated with imatinib and metastasis surgery/RFA may remain disease-free for ≥3 years with improved QoL after stopping of imatinib.
Downloads
References
Demetri GD, von Mehren M, Blanke CD, den Abbeele ADV, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med. 2002;347:472–480.
https://doi.org/10.1056/NEJMoa020461 DOI: https://doi.org/10.1056/NEJMoa020461
Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol. 2017;56:1317–1323.
https://doi.org/10.1080/0284186X.2017.1330555 DOI: https://doi.org/10.1080/0284186X.2017.1330555
Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagno-sis, treatment and follow-up. Ann Oncol. 2021;33:20–33.
https://doi.org/10.1016/j.annonc.2021.09.005 DOI: https://doi.org/10.1016/j.annonc.2021.09.005
Blay JY, Cesne AL, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicen-tric randomize phase III study of imatinib in patients with advanced gastrointes-tinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–1113.
https://doi.org/10.1200/JCO.2006.09.0183 DOI: https://doi.org/10.1200/JCO.2006.09.0183
Cesne AL, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11:942–949.
https://doi.org/10.1016/S1470-2045(10)70222-9 DOI: https://doi.org/10.1016/S1470-2045(10)70222-9
Blay JY, Perol D, Cesne AL. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Ann Oncol. 2012;23:1659–1665. DOI: https://doi.org/10.1093/annonc/mdr622
Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann ThoracSurg. 2009;88:877–885.
https://doi.org/10.1016/j.athoracsur.2009.04.144 DOI: https://doi.org/10.1016/j.athoracsur.2009.04.144
Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21:403–408. DOI: https://doi.org/10.1093/annonc/mdp310
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted system-ic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–2331.
https://doi.org/10.1200/JCO.2005.05.3439 DOI: https://doi.org/10.1200/JCO.2005.05.3439
Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastat-ic/recurrent operable gastrointestinal stromal tumors: long-term follow-up re-sults of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19:1074–1080.
https://doi.org/10.1245/s10434-011-2190-5 DOI: https://doi.org/10.1245/s10434-011-2190-5
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412–419.
https://doi.org/10.1016/j.ejso.2013.12.020 DOI: https://doi.org/10.1016/j.ejso.2013.12.020
Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver me-tastases of gastrointestinal stromal tumors. Surg Today. 2010;40:936–942. DOI: https://doi.org/10.1007/s00595-009-4171-x
Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014;50:1772–1778.
https://doi.org/10.1016/j.ejca.2014.03.280 DOI: https://doi.org/10.1016/j.ejca.2014.03.280
Fauske L, Hompland I, Lorem G, Bondevik H, Bruland ØS. Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. Clin Sarcoma Res. 2019;9:6–8.
https://doi.org/10.1186/s13569-019-0116-3 DOI: https://doi.org/10.1186/s13569-019-0116-3
Dulucq S, Astrugue C, Etienne G, Mahon F, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years. Br J Haematol. 2020;189:452–468.
https://doi.org/10.1111/bjh.16408 DOI: https://doi.org/10.1111/bjh.16408
Hompland I, Bruland ØS. Can imatinib be safely withdrawn in patients with surgically resected metastatic GIST? Anticancer Res. 2015;35:5759–5765.
Kang YK, Kim HD, Kim HJ, Park YS, Beck MY, Ryu MH. Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the ab-sence of gross tumor lesions. Gastric Cancer. 2023;26;604–613. DOI: https://doi.org/10.1007/s10120-023-01377-2
Ramaswamy A, Jain D, Sahu A, Ghosh J, Prasad P, Deodhar K, et al. Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. J Gas-trointest Oncol. 2016;7:624–631.
https://doi.org/10.21037/jgo.2016.03.13 DOI: https://doi.org/10.21037/jgo.2016.03.13
Aghayan DL, Kazaryan AM, Dagenborg VJ, Røsok BI, Fagerland MW, Bjørnelv GMW et al. Long-term oncologic outcomes after laparoscopic versus open resection for colorectal liver metastases: a randomized trial. Ann Intern Med. 2021;174:175–182. DOI: https://doi.org/10.7326/M20-4011
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–382.
https://doi.org/10.1038/nrclinonc.2011.44 DOI: https://doi.org/10.1038/nrclinonc.2011.44
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–625.
https://doi.org/10.1200/JCO.2007.13.4403 DOI: https://doi.org/10.1200/JCO.2007.13.4403
Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–1272. DOI: https://doi.org/10.1001/jama.2012.347
Joensuu H, Eriksson M, Hall KS, Reichardt A, Hermes B, Schütte J, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors. JAMA Oncol. 2020;6:1241–1246.
https://doi.org/10.1001/jamaoncol.2020.2091 DOI: https://doi.org/10.1001/jamaoncol.2020.2091
Joensuu H, Eriksson M, Hall KS, Reichardt A, Hartmann JT, Pink D, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244–250.
https://doi.org/10.1200/JCO.2015.62.9170 DOI: https://doi.org/10.1200/JCO.2015.62.9170
Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group ran-domised, phase III trial. Ann Oncol. 2013;24:1087–1093.
https://doi.org/10.1093/annonc/mds587 DOI: https://doi.org/10.1093/annonc/mds587
Fauske L, Wærstad PH, Hompland I, Bruland ØS. Hope as a lifeline: Imatinib discontinua-tion in patients with oligometastatic gastrointestinal stromal tumours. Antican-cer Res. 2022;42:955–963.
https://doi.org/10.21873/anticanres.15555 DOI: https://doi.org/10.21873/anticanres.15555
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Ivar Hompland, KJetil Boye, Anne Marit Wiedswang, Andri Papakonstantinou, Bård Røsok, Heikki Joensuu, Øyvind Bruland
This work is licensed under a Creative Commons Attribution 4.0 International License.
